Open AccessThe role of EP2 receptors in mediating the ultra-long-lasting intraocular pressure reduction by JV-GL1
Author(s) -
Jacques Bertrand,
David F. Woodward,
Joseph M. Sherwood,
Jenny W. Wang,
Darryl R. Overby
Publication year - 2020
Publication title -
british journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.016
H-Index - 153
eISSN - 1468-2079
pISSN - 0007-1161
DOI - 10.1136/bjophthalmol-2020-317762
Subject(s) - intraocular pressure , glaucoma , receptor , medicine , ocular hypertension , ophthalmology , endocrinology
A single application of JV-GL1 substantially lowers non-human primate intraocular pressure (IOP) for about a week, independent of dose. This highly protracted effect does not correlate with its ocular biodisposition or correlate with the once-daily dosing regimen for other prostanoid EP 2 receptor agonists such as trapenepag or omidenepag. The underlying pharmacological mechanism for the multiday extended activity of JV-GL1 is highly intriguing. The present studies were intended to determine EP 2 receptor involvement in mediating the long-term ocular hypotensive activity of JV-GL1 by using mice genetically deficient in EP 2 receptors.